公开(公告)号：US20120035208A1

公开(公告)日：2012-02-09

申请号：US13129091

申请日：2009-11-19

Applicant: Jennafer Dotson ,  Timothy Heffron ,  Alan G. Olivero ,  Daniel P. Sutherlin ,  Steven Staben ,  Shumei Wang ,  Bing-Yan Zhu ,  Irina S. Chuckowree ,  Adrian J. Folkes ,  Nan Chi Wan

Inventor： Jennafer Dotson ,  Timothy Heffron ,  Alan G. Olivero ,  Daniel P. Sutherlin ,  Steven Staben ,  Shumei Wang ,  Bing-Yan Zhu ,  Irina S. Chuckowree ,  Adrian J. Folkes ,  Nan Chi Wan

IPC: A61K31/437 ,  C12N9/99 ,  A61P35/00 ,  A61P35/02 ,  A61P29/00 ,  A61P3/10 ,  A61P25/00 ,  A61P9/00 ,  A61P1/16 ,  A61P31/12 ,  A61P7/00 ,  C07D471/04 ,  A61P37/02

CPC classification number: C07D471/04

Abstract: Compounds of Formula (I), and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer or inflammation mediated by lipid kinases. Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract translation: 式（I）化合物，并且包括立体异构体，几何异构体，互变异构体，溶剂合物，代谢物和其药学上可接受的盐可用于抑制脂质激酶，包括p110α和PI3K的其他同种型，并用于治疗疾病如癌症或炎症介导 通过脂质激酶。 公开了使用式（I）化合物在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理条件中的这种疾病的方法。

公开(公告)号：US20120022043A1

公开(公告)日：2012-01-26

申请号：US13099179

申请日：2011-05-02

Applicant: Jeffrey Blaney ,  Paul A. Gibbons ,  Emily Hanan ,  Joseph P. Lyssikatos ,  Steven R. Magnuson ,  Richard Pastor ,  Thomas E. Rawson ,  Aihe Zhou ,  Bing-Yan Zhu

Inventor： Jeffrey Blaney ,  Paul A. Gibbons ,  Emily Hanan ,  Joseph P. Lyssikatos ,  Steven R. Magnuson ,  Richard Pastor ,  Thomas E. Rawson ,  Aihe Zhou ,  Bing-Yan Zhu

IPC: A61K31/519 ,  A61K31/5377 ,  A61P37/00 ,  A61P37/06 ,  A61P11/06 ,  A61P17/06 ,  A61P17/00 ,  A61P25/00 ,  C07D487/04 ,  A61P29/00

CPC classification number: C07D487/04

Abstract: The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient.

Abstract translation: 本发明提供了式Ia的JAK激酶抑制剂，其对映体，非对映异构体或其药学上可接受的盐，其中R1，R2，R7和Z在本文中定义，药物组合物包括式Ia化合物和药学上可接受的载体，佐剂或载体 以及对患者中JAK激酶活性的抑制作出反应的疾病或病症的严重程度的治疗或减轻的方法。

公开(公告)号：US08063036B2

公开(公告)日：2011-11-22

申请号：US12756037

申请日：2010-04-07

Applicant: Bing-Yan Zhu ,  Penglie Zhang ,  Lingyan Wang ,  Wenrong Huang ,  Erick A. Goldman ,  Wenhao Li ,  Jingmei Zuckett ,  Yonghong Song ,  Robert M. Scarborough

Inventor： Bing-Yan Zhu ,  Penglie Zhang ,  Lingyan Wang ,  Wenrong Huang ,  Erick A. Goldman ,  Wenhao Li ,  Jingmei Zuckett ,  Yonghong Song ,  Robert M. Scarborough

IPC: C07D401/12 ,  C07D231/02 ,  A61K31/44 ,  A61K31/415

CPC classification number: A61K31/44 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/48 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/616 ,  A61K45/06 ,  A61K2201/094 ,  C07C237/42 ,  C07C255/60 ,  C07C257/18 ,  C07C259/18 ,  C07C311/16 ,  C07C311/46 ,  C07C317/40 ,  C07C317/44 ,  C07D213/75 ,  C07D213/81 ,  C07D213/82 ,  C07D217/22 ,  C07D231/12 ,  C07D233/56 ,  C07D233/64 ,  C07D249/08 ,  C07D295/125 ,  C07D333/38 ,  C07D401/12 ,  C07D409/12 ,  C07D409/14

Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.

Abstract translation: 描述了具有抗哺乳动物因子Xa活性的新型苯甲酰胺化合物，包括其药学上可接受的异构体，盐，水合物，溶剂合物和前药衍生物。 还描述了含有这些化合物的组合物。 化合物和组合物在体外或体内可用于预防或治疗凝血障碍。

公开(公告)号：US07942393B2

公开(公告)日：2011-05-17

申请号：US11788162

申请日：2007-04-19

Applicant: Shu-Yan Zhu ,  Yun-Hui Huang

Inventor： Shu-Yan Zhu ,  Yun-Hui Huang

IPC: B25B1/22

CPC classification number: G02F1/1309

Abstract: An exemplary device (27) for adjusting angle of a base plate (2710) includes: two side walls (21) being parallel to and spaced apart from each other, each of the side walls including a pivot hole (217); a base plate disposed between the two side walls and pivotally attached to the side walls via the pivot axles; and a plurality of magnetism members (211, 212 and 2715) disposed on the base plate (2710) and the side wall. The magnetism members configures for holding the base plate stably in a starting position and further configures to allow the base plate to be displaced from the starting position by manual pressure applied to the base plate, such that a tilt angle of the base plate relative to the two side walls is adjustable up or down as desired. An exemplary apparatus (2) for testing display modules using the angle adjusting device is also provided.

Abstract translation: 用于调节基板（2710）的角度的示例性装置（27）包括：彼此平行并间隔开的两个侧壁（21），每个侧壁包括枢轴孔（217）; 设置在所述两个侧壁之间并且经由所述枢转轴可枢转地附接到所述侧壁的基板; 以及设置在基板（2710）和侧壁​​上的多个磁性构件（211,212和2715）。 磁性构件用于将基板稳定地保持在起始位置，并且进一步构造成允许基板通过施加到基板的手动压力从起始位置移位，使得基板相对于底板的倾斜角度 两个侧壁可根据需要上下调节。 还提供了用于使用角度调节装置测试显示模块的示例性装置（2）。

公开(公告)号：US20110112085A1

公开(公告)日：2011-05-12

申请号：US13006217

申请日：2011-01-13

Applicant: Georgette M. Castanedo ,  Janet L. Gunzner ,  Kimberly Malesky ,  Simon Mathieu ,  Alan G. Olivero ,  Daniel P. Sutherlin ,  Shumei Wang ,  Bing-Yan Zhu ,  Irina Chuckowree ,  Adrian Folkes ,  Sally Oxenford ,  Nan-Chi Wan

Inventor： Georgette M. Castanedo ,  Janet L. Gunzner ,  Kimberly Malesky ,  Simon Mathieu ,  Alan G. Olivero ,  Daniel P. Sutherlin ,  Shumei Wang ,  Bing-Yan Zhu ,  Irina Chuckowree ,  Adrian Folkes ,  Sally Oxenford ,  Nan-Chi Wan

IPC: A61K31/5377 ,  A61P35/00 ,  A61P35/02

CPC classification number: C07D513/04

Abstract: Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract translation: 式Ia和Ib的化合物，并且包括立体异构体，几何异构体，互变异构体，溶剂合物，代谢物和药学上可接受的盐可用于抑制脂质激酶（包括PI3K）和用于治疗由脂质激酶介导的癌症等疾病。 公开了将式Ia和Ib化合物用于体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

公开(公告)号：US20100298284A1

公开(公告)日：2010-11-25

申请号：US12756037

申请日：2010-04-07

Applicant: Bing-Yan ZHU ,  Penglie ZHANG ,  Lingyan WANG ,  Wenrong HUANG ,  Erick A. GOLDMAN ,  Wenhao LI ,  Jingmei ZUCKETT ,  Yonghong SONG ,  Robert M. SCARBOROUGH

Inventor： Bing-Yan ZHU ,  Penglie ZHANG ,  Lingyan WANG ,  Wenrong HUANG ,  Erick A. GOLDMAN ,  Wenhao LI ,  Jingmei ZUCKETT ,  Yonghong SONG ,  Robert M. SCARBOROUGH

IPC: A61K31/44 ,  C07D213/75 ,  A01N1/02 ,  C07C317/24 ,  A61K31/245 ,  C07D401/12 ,  A61K31/444 ,  A61K31/496 ,  C07D413/12 ,  A61K31/5377 ,  A61K31/4427 ,  A61K31/541 ,  C07D417/12 ,  A61K31/551 ,  A61K31/55 ,  C07D217/22 ,  A61K31/472

CPC classification number: A61K31/44 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/48 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/616 ,  A61K45/06 ,  A61K2201/094 ,  C07C237/42 ,  C07C255/60 ,  C07C257/18 ,  C07C259/18 ,  C07C311/16 ,  C07C311/46 ,  C07C317/40 ,  C07C317/44 ,  C07D213/75 ,  C07D213/81 ,  C07D213/82 ,  C07D217/22 ,  C07D231/12 ,  C07D233/56 ,  C07D233/64 ,  C07D249/08 ,  C07D295/125 ,  C07D333/38 ,  C07D401/12 ,  C07D409/12 ,  C07D409/14

Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.

Abstract translation: 描述了具有抗哺乳动物因子Xa活性的新型苯甲酰胺化合物，包括其药学上可接受的异构体，盐，水合物，溶剂合物和前药衍生物。 还描述了含有这些化合物的组合物。 化合物和组合物在体外或体内可用于预防或治疗凝血障碍。

公开(公告)号：US20100132905A1

公开(公告)日：2010-06-03

申请号：US12698844

申请日：2010-02-02

Applicant: Arnie FULTON ,  Yan ZHU ,  Michael BOMAR

Inventor： Arnie FULTON ,  Yan ZHU ,  Michael BOMAR

IPC: B22D46/00 ,  B22D2/00

CPC classification number: B22D17/32 ,  B22D46/00

Abstract: A die casting process using pattern recognition techniques to identify those die castings manufactured under conditions likely to produce a die casting which would subsequently prove unacceptable for use. By promptly identifying such die castings, they may be discarded before being shipped to a remote facility for further processing. As a result, the rejection rate of die castings at the remote facility may be reduced and the raw materials used to form the discarded die castings may be more readily recycled.

Abstract translation: 使用模式识别技术的压铸方法来识别在可能产生压铸件的条件下制造的那些压铸件，随后将被证明是不可接受的。 通过及时识别这种压铸件，在运送到远程设备进行进一步处理之前，可将其丢弃。 结果，可以减少远程设备的压铸件的排出率，并且用于形成废弃压铸件的原材料可以更容易地再循环。

公开(公告)号：US07727982B2

公开(公告)日：2010-06-01

申请号：US11488455

申请日：2006-07-17

Applicant: Bing-Yan Zhu ,  Penglie Zhang ,  Lingyan Wang ,  Wenrong Huang ,  Erick A. Goldman ,  Wenhao Li ,  Jingmei Zuckett ,  Yonghong Song ,  Robert M. Scarborough

Inventor： Bing-Yan Zhu ,  Penglie Zhang ,  Lingyan Wang ,  Wenrong Huang ,  Erick A. Goldman ,  Wenhao Li ,  Jingmei Zuckett ,  Yonghong Song ,  Robert M. Scarborough

IPC: C07D243/02 ,  C07D401/02 ,  A61K31/44

CPC classification number: A61K31/44 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/48 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/616 ,  A61K45/06 ,  A61K2201/094 ,  C07C237/42 ,  C07C255/60 ,  C07C257/18 ,  C07C259/18 ,  C07C311/16 ,  C07C311/46 ,  C07C317/40 ,  C07C317/44 ,  C07D213/75 ,  C07D213/81 ,  C07D213/82 ,  C07D217/22 ,  C07D231/12 ,  C07D233/56 ,  C07D233/64 ,  C07D249/08 ,  C07D295/125 ,  C07D333/38 ,  C07D401/12 ,  C07D409/12 ,  C07D409/14

Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compound and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.

Abstract translation: 描述了具有抗哺乳动物因子Xa活性的新型苯甲酰胺化合物，包括其药学上可接受的异构体，盐，水合物，溶剂合物和前药衍生物。 还描述了含有这些化合物的组合物。 化合物和组合物可用于体外或体内用于预防或治疗凝血障碍。

公开(公告)号：US07723470B2

公开(公告)日：2010-05-25

申请号：US11977377

申请日：2007-10-24

Applicant: J. Kevin Judice ,  Paul Ross Fatheree ,  Bernice M. T. Lam ,  Michael R. Leadbetter ,  Martin S. Linsell ,  YongQi Mu ,  Sean Gary Trapp ,  Guang Yang ,  Yan Zhu

Inventor： J. Kevin Judice ,  Paul Ross Fatheree ,  Bernice M. T. Lam ,  Michael R. Leadbetter ,  Martin S. Linsell ,  YongQi Mu ,  Sean Gary Trapp ,  Guang Yang ,  Yan Zhu

IPC: C07K7/50

CPC classification number: C07K9/008 ,  A61K38/00 ,  C07K7/06

Abstract: Disclosed are compounds of the formula: or a trifluoroacetic acid salt thereof, wherein A, B and Fmoc are as defined herein. Such compounds are useful as synthetic intermediates for preparing glycopeptides antibiotics.

Abstract translation: 公开了下式的化合物或其三氟乙酸盐，其中A，B和Fmoc如本文所定义。 这些化合物可用作制备糖肽抗生素的合成中间体。

公开(公告)号：US07677295B2

公开(公告)日：2010-03-16

申请号：US12049057

申请日：2008-03-14

Applicant: Arnie Fulton ,  Yan Zhu ,  Michael Bomar

Inventor： Arnie Fulton ,  Yan Zhu ,  Michael Bomar

IPC: B22D46/00

CPC classification number: B22D17/32 ,  B22D46/00

Abstract: A die casting process using pattern recognition techniques to identify those die castings manufactured under conditions likely to produce a die casting which would subsequently prove unacceptable for use. By promptly identifying such die castings, they may be discarded before being shipped to a remote facility for further processing. As a result, the rejection rate of die castings at the remote facility may be reduced and the raw materials used to form the discarded die castings may be more readily recycled.

Abstract translation: 使用模式识别技术的压铸方法来识别在可能产生压铸件的条件下制造的那些压铸件，随后将被证明是不可接受的。 通过及时识别这种压铸件，在运送到远程设备进行进一步处理之前，可将其丢弃。 结果，可以减少远程设备的压铸件的排出率，并且用于形成废弃压铸件的原材料可以更容易地再循环。